GLP-1s often work better for both goals
The bioavailability gap means that nasal doses cannot simply mirror standard retatrutide dosing protocols
Continuous treatment is needed to maintain improvement in weight and health. Eli Lilly, frontrunner in commercializing GLP-1 analogs, eyes obesity treatment market Eli Lilly has long dominated the GLP-1 analog market with its diabetes treatment Trulicity (dulaglutide)
Nutrition Serving Size: 1 small bowl Calories: 90 Sugar: 4g Sodium: 220mg Fat: 5g Saturated Fat: 1g Unsaturated Fat: 3g Trans Fat: 0g Carbohydrates: 8g Fiber: 2g Protein: 4g Cholesterol: 2mg
When we look at the big picture, it looks like the deck is stacked against us
On August 1, 2024, North Carolina Medicaid launched coverage for glucagon-like peptide 1 (GLP-1s) drugs for weight loss despite the State Health Plan (SHP) ending coverage on April 1, 2024